Podcast Episodes
Back to Search
FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More
The FDA is working to reapprove GSK’s long-dormant drug Wellcovorin (leucovorin) for cerebral folate deficiency, which the agency linked to “developm…
9 months, 2 weeks ago
What Do AI and Hammers Have in Common?
In this episode, Lori Ellis and Colin Zick spend a little time further discussing some of the points brought up in the Bioprocessing Summit last mont…
9 months, 3 weeks ago
China Crackdown, UK Exit, Novo Layoffs, Adcomm Flip Flop, More
A global shift may be underway in biopharma as the White House prepares legislation that would would place restrictions on drugs brought to the U.S. …
9 months, 3 weeks ago
Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
The Make America Healthy Again Commission released itssecond report Tuesday, recommending, among other efforts, an investigation into a possible link…
10 months ago
The 'Research Safety Net' Saving Scientists from Funding Crisis
In this episode, Mike Garrett, CEO of Taconic Biosciences, discusses how preclinical research companies are helping drug developers navigate the curr…
10 months ago
CDC Faces Critical Meetings Amid COVID Vaccine Uncertainty, Plus Deals, FDA Approvals, More
We returned from the Labor Day holiday to a spate of intriguing deals, including two that could surpass $2 billion: Vertex’s new pact with Enlaza for…
10 months, 1 week ago
Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change
Eli Lilly posted data Tuesday from a second Phase III trial of its oral weight loss therapy orforglipron, providing the company with all it needs to …
10 months, 1 week ago
Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations
Oral therapies are projected to account for 25% of the anti-obesity medication market by 2030—but first returns have largely disappointed. This month…
10 months, 2 weeks ago
Why AI Won't Save the 90% of Clinical Trials That Still Fail
While AI represents a significant advancement in efficiency for early-stage drug discovery, it won't dramatically change the 90% clinical trial failu…
10 months, 2 weeks ago
MAHA Report Emphasizes Vaccines, Safety Vexes Viking’s Obesity Win, Novo Gains Momentum
Three months after taking heat over an error-riddled first report, Health Secretary Robert F. Kennedy’s Make America Healthy Again Commission was due…
10 months, 2 weeks ago